Floatz logo

2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE

Cirrhosis

Can-Fite BioPharmaSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Cirrhosis cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 3A
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
King George's Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
60 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →